NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
Clinical Trials
19 trialsNCT04136912 2025-10-06
3-D Super Resolution Ultrasound Microvascular Imaging
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT03127098 2024-08-06
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
Phase 1/2 Terminated
NCT04161391 2024-06-13
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
NCT04327999 2024-01-18
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT03065218 2022-07-26
99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients
Medstar Health Research Institute
Phase 4 Terminated
NCT03131206 2021-09-27
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03463889 2021-06-29
Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02946918 2020-12-01
Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy
University of Texas Southwestern Medical Center
Phase 4 Terminated
NCT03002623 2018-12-21
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00100828 2018-12-06
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00923247 2018-11-29
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00416949 2018-07-18
Iodine I 131 in Treating Patients With Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Terminated
NCT00126568 2018-01-19
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01838642 2017-02-15
Ponatinib for Advanced Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00507429 2014-06-09
FACT
Mateon Therapeutics
Phase 2/3 Terminated
NCT00115739 2014-04-21
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated